The Marked Chart Wire · Health
Cytokinetics
Fda clears label change for Cytokinetics heart medication
The agency approved an update to MYQORZO's labeling, incorporating results from the MAPLE-HCM trial that compared aficamten with metoprolol in patients with obstructive hypertrophic cardiomyopathy.
